Equities

Interpace Biosciences Inc

Interpace Biosciences Inc

Actions
Health CareHealth Care Providers
  • Price (USD)3.28
  • Today's Change0.29 / 9.70%
  • Shares traded20.39k
  • 1 Year change+198.18%
  • Beta0.7473
Data delayed at least 15 minutes, as of Nov 13 2024 20:53 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Interpace Biosciences, Inc. provides personalized medicine and offers specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating the risk of cancer by leveraging the technology in personalized medicine for improved patient diagnosis and management. It has five commercialized molecular tests and one test in a clinical evaluation program: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, RespriDX, and BarreGEN. PancraGEN is for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts. PanDNA is a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors. ThyGeNEXT is for the diagnosis of thyroid cancer from thyroid nodules. RespriDX differentiates lung cancer of primary versus metastatic origin.

  • Revenue in USD (TTM)44.89m
  • Net income in USD4.89m
  • Incorporated1998
  • Employees108.00
  • Location
    Interpace Biosciences IncWaterview PlazaSuite 310, 2001 Route 46PARSIPPANY 07054United StatesUSA
  • Phone+1 (412) 224-6100
  • Fax+1 (302) 636-5454
  • Websitehttps://www.interpace.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Univec Inc-100.00bn-100.00bn7.32m3.00---------------0.0113-----------50.96------17.47---198.310.0051-------74.07-64.8336.83------
Ontrak Inc12.39m-36.52m7.93m102.00--0.3901--0.6403-35.26-35.264.584.820.5173--12.53121,421.60-115.11-54.80-157.11-73.3766.8153.50-222.54-71.95---1.730.3021---12.20-3.4439.08--99.58--
Healthlynked Corp4.06m-4.38m8.18m38.00------2.01-0.0158-0.01590.0148-0.00150.865915.3340.39106,922.10-93.24-119.37-327.73-332.2252.3155.81-107.68-119.260.5622--2.15---2.3220.4357.08---12.94--
ATI Physical Therapy Inc741.86m-79.62m10.01m6.00k------0.0135-18.57-18.57174.1717.200.7625--8.02123,643.80-5.49---6.39--16.13---7.21----0.19050.8762--9.97--73.20------
Streamline Health Solutions Inc20.30m-18.82m10.05m77.00--9.48--0.495-0.3277-0.32770.34990.25110.4397--7.64263,636.40-40.77-22.06-56.63-31.6950.8649.96-92.72-54.55---4.460.4395---9.210.2057-64.31---11.72--
Pacific Health Care Organization Inc6.17m869.09k10.24m30.0011.800.898911.301.660.06780.06780.48120.890.5259--6.40205,557.707.417.297.937.8179.0382.7514.0913.28----0.00---2.00-3.7055.80-10.80-15.93--
Aesthetic Medical Intl Hldg Grp Ltd(ADR)100.58m-6.70m11.95m1.29k--3.106.020.1188-0.1487-0.14872.220.08071.2920.8277.3678,214.39-9.06-23.36-35.45-48.5845.3955.32-7.02-23.720.2031-5.500.9581--1.86-2.1650.91--3.70--
Elite Health Systems Inc0.00-1.02m13.48m2.00--6.75-----0.0928-0.09280.000.14820.00----0.00-45.80-14.62-66.91-19.89-------36.77----0.00------38.97------
Psychemedics Corp.20.79m-4.56m13.82m116.00--2.38--0.665-0.7882-0.78823.590.98581.57--5.89179,198.30-34.41-7.44-53.29-9.7037.6337.55-21.93-6.26---264.690.1198---12.45-12.33-283.21---33.32--
Interpace Biosciences Inc44.89m4.89m14.45m108.002.97--2.800.32181.101.0610.13--------415,675.90---38.19---69.7360.4649.4410.88-41.01--8.11----26.3112.93118.96--0.9184--
PharmChem Inc5.98m1.14m14.97m170.0013.345.4513.122.500.24140.24141.260.59031.839.258.71--34.87--42.91--64.49--19.05--5.20--0.00--3.50---16.95------
ProPhase Labs Inc17.97m-26.31m17.90m113.00--0.3333--0.9961-1.46-1.460.99622.310.19465.240.5027159,044.30-28.480.9106-36.781.12-9.1150.32-146.390.93251.44-17.990.2469665.78-63.8127.59-190.90--86.46--
Oncology Institute Inc361.07m-58.51m19.91m800.00--0.6819--0.0552-0.7898-0.78984.870.38691.7626.037.19451,333.80-34.94---41.97--15.3319.54-19.81-9.992.99-7.800.7549--28.4223.43-99,919.12--45.68--
Data as of Nov 13 2024. Currency figures normalised to Interpace Biosciences Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.